We are pleased to share a recent milestone from Oxford Cancer Biomarkers (OCB), a University of Oxford spin-out and a portfolio company of Plutus Investment Group LLP.

OCB has announced the expanded clinical utility of its proprietary ToxNav® test, strengthening its ability to predict chemotherapy-related toxicity and support safer, more personalised cancer treatment.

This development follows a Licence of Technology agreement with Oxford University Innovation, enabling OCB to extend its intellectual property and broaden the clinical application of ToxNav® beyond existing standards of care.

With strong academic foundations, validated clinical relevance, and growing international adoption, OCB continues to demonstrate the type of high-impact, precision-medicine innovation we seek to support at Plutus.